In a recent development that sent shockwaves through the pharmaceutical industry, Novavax Inc (NASDAQ: NVAX) saw a 20% drop in its shares on Friday. The cause? The Food and Drug Administration (FDA) raised concerns about the potential risk of heart inflammation linked to Novavax’s COVID-19 vaccine. This revelation came as part of a briefing document...